{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T19:53:00Z","timestamp":1789069980314,"version":"build-2803163510"},"reference-count":62,"publisher":"Elsevier BV","issue":"14","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Phytomedicine"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.phymed.2015.11.001","type":"journal-article","created":{"date-parts":[[2015,11,11]],"date-time":"2015-11-11T02:57:27Z","timestamp":1447210647000},"page":"1223-1231","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"title":["Activity of Artemisia annua and artemisinin derivatives, in prostate carcinoma"],"prefix":"10.1016","volume":"22","author":[{"given":"Friedrich-Wilhelm","family":"Michaelsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed E.M.","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Schwarzkopf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Efferth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phymed.2015.11.001_bib0001","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1002\/cncr.24395","article-title":"Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival","volume":"115","author":"Akaza","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.phymed.2015.11.001_bib0002","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1158\/0008-5472.CAN-07-2120","article-title":"Integrating global gene expression and radiation survival parameters across the 60 cell lines of the National Cancer Institute Anticancer Drug Screen","volume":"68","author":"Amundson","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.phymed.2015.11.001_bib0003","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0009-8981(89)90077-6","article-title":"Serum CK-BB as a tumor marker in patients with carcinoma confirmed histologically","volume":"182","author":"Arenas","year":"1989","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.phymed.2015.11.001_bib0004","doi-asserted-by":"crossref","first-page":"e20550","DOI":"10.1371\/journal.pone.0020550","article-title":"Development of resistance towards artesunate in MDA-MB-231 human breast cancer cells","volume":"6","author":"Bachmeier","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.phymed.2015.11.001_bib0005","doi-asserted-by":"crossref","first-page":"823","DOI":"10.4269\/ajtmh.1998.59.823","article-title":"A pharmacokinetic and pharmacodynamic study of artesunate for vivax malaria","volume":"59","author":"Batty","year":"1998","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.phymed.2015.11.001_bib0006","first-page":"1599","article-title":"Artesunate in the treatment of metastatic uveal melanoma\u2013first experiences","volume":"14","author":"Berger","year":"2005","journal-title":"Oncol Rep"},{"key":"10.1016\/j.phymed.2015.11.001_bib0007","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s13659-014-0013-7","article-title":"Treatment of Iron-Loaded Veterinary Sarcoma by Artemisia annua","volume":"4","author":"Breuer","year":"2014","journal-title":"Nat. Prod. Bioprospect."},{"key":"10.1016\/j.phymed.2015.11.001_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000076256","article-title":"Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR\/flk-1","volume":"71","author":"Chen","year":"2004","journal-title":"Pharmacology"},{"key":"10.1016\/j.phymed.2015.11.001_bib0009","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/bdrb.20282","article-title":"Artesunate and artelinic acid: association of embryotoxicity, reticulocytopenia, and delayed stimulation of hematopoiesis in pregnant rats","volume":"92","author":"Clark","year":"2011","journal-title":"Birth Defects Res. B Dev. Reprod. Toxicol."},{"key":"10.1016\/j.phymed.2015.11.001_bib0010","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/pros.2990250503","article-title":"Bone alkaline phosphatase and prostate-specific antigen in the monitoring of prostate cancer","volume":"25","author":"Cooper","year":"1994","journal-title":"Prostate"},{"key":"10.1016\/j.phymed.2015.11.001_bib0011","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/bju.12061","article-title":"The utility of prostate-specific antigen in the management of advanced prostate cancer","volume":"112","author":"Crawford","year":"2013","journal-title":"BJU Int."},{"key":"10.1016\/j.phymed.2015.11.001_bib0012","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1016\/j.bcp.2004.08.021","article-title":"Inhibition of angiogenesis in vivo and growth of Kaposi's sarcoma xenograft tumors by the anti-malarial artesunate","volume":"68","author":"Dell'Eva","year":"2004","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.phymed.2015.11.001_bib0013","doi-asserted-by":"crossref","first-page":"10854","DOI":"10.1158\/0008-5472.CAN-05-1216","article-title":"Dihydroartemisinin is cytotoxic to papillomavirus-expressing epithelial cells in vitro and in vivo","volume":"65","author":"Disbrow","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.phymed.2015.11.001_bib0014","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s00280-009-1095-5","article-title":"Artesunate induces oncosis-like cell death in vitro and has antitumor activity against pancreatic cancer xenografts in vivo","volume":"65","author":"Du","year":"2010","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.phymed.2015.11.001_bib0015","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.freeradbiomed.2004.06.023","article-title":"Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron","volume":"37","author":"Efferth","year":"2004","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.phymed.2015.11.001_bib0016","first-page":"767","article-title":"The anti-malarial artesunate is also active against cancer","volume":"18","author":"Efferth","year":"2001","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.phymed.2015.11.001_bib0017","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/sj.leu.2400669","article-title":"Apoptosis and resistance to daunorubicin in human leukemic cells","volume":"11","author":"Efferth","year":"1997","journal-title":"Leukemia"},{"key":"10.1016\/j.phymed.2015.11.001_bib0018","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3109\/10408441003610571","article-title":"Toxicity of the antimalarial artemisinin and its dervatives","volume":"40","author":"Efferth","year":"2010","journal-title":"Crit. Rev. Toxicol."},{"key":"10.1016\/j.phymed.2015.11.001_bib0019","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0006-2952(02)01221-2","article-title":"mRNA expression profiles for the response of human tumor cell lines to the antimalarial drugs artesunate, arteether, and artemether","volume":"64","author":"Efferth","year":"2002","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.phymed.2015.11.001_bib0020","first-page":"196","article-title":"Detection of apoptosis in KG-1a leukemic cells treated with investigational drugs","volume":"46","author":"Efferth","year":"1996","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.phymed.2015.11.001_bib0021","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1124\/mol.64.2.382","article-title":"Molecular modes of action of artesunate in tumor cell lines","volume":"64","author":"Efferth","year":"2003","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.phymed.2015.11.001_bib0022","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1002\/cmdc.201200383","article-title":"Interactions between artemisinins and other antimalarial drugs in relation to the cofactor model\u2013a unifying proposal for drug action","volume":"7","author":"Haynes","year":"2012","journal-title":"ChemMedChem"},{"key":"10.1016\/j.phymed.2015.11.001_bib0023","doi-asserted-by":"crossref","first-page":"819","DOI":"10.4161\/cbt.9.10.11552","article-title":"Dihydroartemisinin upregulates death receptor 5 expression and cooperates with TRAIL to induce apoptosis in human prostate cancer cells","volume":"9","author":"He","year":"2010","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.phymed.2015.11.001_bib0024","first-page":"4417","article-title":"First study of oral Artenimol-R in advanced cervical cancer: clinical benefit, tolerability and tumor markers","volume":"31","author":"Jansen","year":"2011","journal-title":"Anticancer Res."},{"key":"10.1016\/j.phymed.2015.11.001_bib0025","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/pros.20276","article-title":"Expression of vascular endothelial growth factor C (VEGF-C) and VEGF receptor-3 in human prostate cancer is associated with regional lymph node metastasis","volume":"65","author":"Jennbacken","year":"2005","journal-title":"Prostate"},{"key":"10.1016\/j.phymed.2015.11.001_bib0026","doi-asserted-by":"crossref","first-page":"315","DOI":"10.4111\/kju.2014.55.5.315","article-title":"Efficacy of Bicalutamide 150-mg monotherapy compared with combined androgen blockade in patients with locally advanced prostate cancer","volume":"55","author":"Kang","year":"2014","journal-title":"Korean J. Urol."},{"key":"10.1016\/j.phymed.2015.11.001_bib0027","doi-asserted-by":"crossref","first-page":"e798","DOI":"10.1371\/journal.pone.0000798","article-title":"Role of transferrin receptor and the ABC transporters ABCB6 and ABCB7 for resistance and differentiation of tumor cells towards artesunate","volume":"2","author":"Kelter","year":"2007","journal-title":"PLoS One"},{"key":"10.1016\/j.phymed.2015.11.001_bib0028","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/pcan.2014.24","article-title":"An open-label, phase 2 trial of bicalutamide dose escalation from 50\u00a0mg to 150\u00a0mg in men with CAB and castration resistance","volume":"17","author":"Klotz","year":"2014","journal-title":"A Can. Urol. Res. Consort. Study. Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.phymed.2015.11.001_bib0029","doi-asserted-by":"crossref","first-page":"72","DOI":"10.2174\/156800909787314020","article-title":"The role of downstream signaling pathways of the epidermal growth factor receptor for Artesunate's activity in cancer cells","volume":"9","author":"Konkimalla","year":"2009","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.phymed.2015.11.001_bib0030","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ebiom.2014.11.010","article-title":"A randomised, double blind, placebo-controlled pilot study of oral artesunate therapy for colorectal cancer","volume":"2","author":"Krishna","year":"2015","journal-title":"EBioMed."},{"key":"10.1016\/j.phymed.2015.11.001_bib0031","doi-asserted-by":"crossref","unstructured":"Krishna S, G.S., Ster IC, Saeed MEM, Cowan M, Finlayson C, Kovacsevics H, Jansen H, Kremsner PG, Efferth T, Kumar D., 2014. A randomized, double-blind, placebo-controlled pilot study of oral artesunate therapy for colorectal cancer., EBioMedicine","DOI":"10.1016\/j.ebiom.2014.11.010"},{"key":"10.1016\/j.phymed.2015.11.001_bib0032","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.canlet.2005.01.019","article-title":"Oral artemisinin prevents and delays the development of 7,12-dimethylbenz[a]anthracene (DMBA)-induced breast cancer in the rat","volume":"231","author":"Lai","year":"2006","journal-title":"Cancer Lett."},{"key":"10.1016\/j.phymed.2015.11.001_bib0033","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1002\/ijc.22804","article-title":"Artesunate attenuates the growth of human colorectal carcinoma and inhibits hyperactive Wnt\/beta-catenin pathway","volume":"121","author":"Li","year":"2007","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.phymed.2015.11.001_bib0034","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tox.2010.09.005","article-title":"Toxicokinetic and toxicodynamic (TK\/TD) evaluation to determine and predict the neurotoxicity of artemisinins","volume":"279","author":"Li","year":"2011","journal-title":"Toxicology"},{"key":"10.1016\/j.phymed.2015.11.001_bib0035","doi-asserted-by":"crossref","first-page":"10556","DOI":"10.3390\/molecules161210556","article-title":"The effects of artesunate on the expression of EGFR and ABCG2 in A549 human lung cancer cells and a xenograft model","volume":"16","author":"Ma","year":"2011","journal-title":"Molecules"},{"key":"10.1016\/j.phymed.2015.11.001_bib0036","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1126\/science.1260403","article-title":"Drug resistance. Population transcriptomics of human malaria parasites reveals the mechanism of artemisinin resistance.","volume":"347","author":"Mok","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.phymed.2015.11.001_bib0037","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/jnci\/83.11.757","article-title":"Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines","volume":"83","author":"Monks","year":"1991","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.phymed.2015.11.001_bib0038","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0304-3835(06)80014-5","article-title":"Oral administration of dihydroartemisinin and ferrous sulfate retarded implanted fibrosarcoma growth in the rat","volume":"98","author":"Moore","year":"1995","journal-title":"Cancer Lett."},{"key":"10.1016\/j.phymed.2015.11.001_bib0039","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1002\/pros.21204","article-title":"The relationship between proangiogenic gene expression levels in prostate cancer and their prognostic value for clinical outcomes","volume":"70","author":"Mori","year":"2010","journal-title":"Prostate"},{"key":"10.1016\/j.phymed.2015.11.001_bib0040","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/CAD.0b013e328336f57b","article-title":"Effect of artemisinin derivatives on apoptosis and cell cycle in prostate cancer cells","volume":"21","author":"Morrissey","year":"2010","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.phymed.2015.11.001_bib0041","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1111\/j.1464-410X.2012.11456.x","article-title":"Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer","volume":"110","author":"Nakabayashi","year":"2012","journal-title":"BJU Int."},{"key":"10.1016\/j.phymed.2015.11.001_bib0042","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/j.phymed.2014.07.018","article-title":"Anti-malarial drug artesunate protects against cigarette smoke-induced lung injury in mice","volume":"21","author":"Ng","year":"2014","journal-title":"Phytomedicine"},{"key":"10.1016\/j.phymed.2015.11.001_bib0043","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.phymed.2015.08.002","article-title":"Artemisinin derivatives induce iron-dependent cell death (ferroptosis) in tumor cells","volume":"22","author":"Ooko","year":"2015","journal-title":"Phytomedicine"},{"key":"10.1016\/j.phymed.2015.11.001_bib0044","first-page":"2807","article-title":"Development of a dihydroartemisinin-resistant Molt-4 leukemia cell line","volume":"34","author":"Park","year":"2014","journal-title":"Anticancer Res."},{"key":"10.1016\/j.phymed.2015.11.001_bib0045","first-page":"110","article-title":"Report on a cooperative study of nitrogen mustard (HN2) therapy of neoplastic disease","volume":"60","author":"Rhoads","year":"1947","journal-title":"Trans. Assoc. Am. Phys."},{"key":"10.1016\/j.phymed.2015.11.001_bib0046","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1159\/000369545","article-title":"Prognostic impact of C-reactive protein in metastatic prostate cancer: a systematic review and meta-analysis","volume":"37","author":"Rocha","year":"2014","journal-title":"Oncol. Res. Treat."},{"key":"10.1016\/j.phymed.2015.11.001_bib0047","first-page":"1819","article-title":"Safety and efficacy field study of artesunate for dogs with non-resectable tumours","volume":"33","author":"Rutteman","year":"2013","journal-title":"Anticancer Res."},{"key":"10.1016\/j.phymed.2015.11.001_bib0048","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/73439","article-title":"A gene expression database for the molecular pharmacology of cancer","volume":"24","author":"Scherf","year":"2000","journal-title":"Nat. Genet."},{"key":"10.1016\/j.phymed.2015.11.001_bib0049","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.3390\/molecules15042886","article-title":"Pharmacogenomic identification of c-Myc\/Max-regulated genes associated with cytotoxicity of artesunate towards human colon, ovarian and lung cancer cell lines","volume":"15","author":"Sertel","year":"2010","journal-title":"Molecules"},{"key":"10.1016\/j.phymed.2015.11.001_bib0050","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/pros.2990020111","article-title":"Creatine kinase BB and other markers of prostatic carcinoma","volume":"2","author":"Silverman","year":"1981","journal-title":"Prostate"},{"key":"10.1016\/j.phymed.2015.11.001_bib0051","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2298\/AOO0204279S","article-title":"Case report of a laryngeal squamous cell carcinoma treated with artesunate","volume":"10","author":"Singh","year":"2002","journal-title":"Arch. Oncol"},{"key":"10.1016\/j.phymed.2015.11.001_bib0052","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.clgc.2014.06.001","article-title":"A phase II study of GW786034 (Pazopanib) with or without bicalutamide in patients with castration-resistant prostate cancerClin","volume":"13","author":"Sridhar","year":"2015","journal-title":"Clin. Genitourin Cancer."},{"key":"10.1016\/j.phymed.2015.11.001_bib0053","doi-asserted-by":"crossref","first-page":"717","DOI":"10.4269\/ajtmh.2001.65.717","article-title":"Comparative pharmacokinetics and effect kinetics of orally administered artesunate in healthy volunteers and patients with uncomplicated falciparum malaria","volume":"65","author":"Teja-Isavadharm","year":"2001","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.phymed.2015.11.001_bib0054","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.2174\/1568026043387610","article-title":"The use of DNA microarrays to investigate the pharmacogenomics of drug response in living systems","volume":"4","author":"Villeneuve","year":"2004","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.phymed.2015.11.001_bib0055","first-page":"157","article-title":"Prediction of drug sensitivity and resistance of cancer by protein expression profiling","volume":"1","author":"Volm","year":"2004","journal-title":"Cancer Genom. Proteom."},{"key":"10.1016\/j.phymed.2015.11.001_bib0056","doi-asserted-by":"crossref","first-page":"e609","DOI":"10.1016\/j.ijrobp.2011.09.002","article-title":"Phase II study of long-term androgen suppression with bevacizumab and intensity-modulated radiation therapy (IMRT) in high-risk prostate cancer","volume":"82","author":"Vuky","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys"},{"key":"10.1016\/j.phymed.2015.11.001_bib0057","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1111\/j.1464-410X.2010.09726.x","article-title":"Bicalutamide monotherapy preserves bone mineral density, muscle strength and has significant health-related quality of life benefits for osteoporotic men with prostate cancer","volume":"107","author":"Wadhwa","year":"2011","journal-title":"BJU Int."},{"key":"10.1016\/j.phymed.2015.11.001_bib0058","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1074\/jbc.M804491200","article-title":"Artemisinin blocks prostate cancer growth and cell cycle progression by disrupting Sp1 interactions with the cyclin-dependent kinase-4 (CDK4) promoter and inhibiting CDK4 gene expression","volume":"284","author":"Willoughby","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phymed.2015.11.001_bib0059","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1186\/s13059-014-0544-6","article-title":"Drug resistance genomics of the antimalarial drug artemisinin","volume":"15","author":"Winzeler","year":"2014","journal-title":"Genome Biol."},{"key":"10.1016\/j.phymed.2015.11.001_bib0060","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1745-7262.2006.00120.x","article-title":"Increased expressions of vascular endothelial growth factor (VEGF), VEGF-C and VEGF receptor-3 in prostate cancer tissue are associated with tumor progression","volume":"8","author":"Yang","year":"2006","journal-title":"Asian J. Androl."},{"key":"10.1016\/j.phymed.2015.11.001_bib0061","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1471-2105-12-52","article-title":"RedundancyMiner: De-replication of redundant GO categories in microarray and proteomics analysis","volume":"12","author":"Zeeberg","year":"2011","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.phymed.2015.11.001_bib0062","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3736\/jcim20080206","article-title":"[Artesunate combined with vinorelbine plus cisplatin in treatment of advanced non-small cell lung cancer: a randomized controlled trial]","volume":"6","author":"Zhang","year":"2008","journal-title":"Zhong Xi Yi Jie He Xue Bao"}],"container-title":["Phytomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0944711315003323?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0944711315003323?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T12:14:06Z","timestamp":1567340046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0944711315003323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":62,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S0944711315003323"],"URL":"https:\/\/doi.org\/10.1016\/j.phymed.2015.11.001","relation":{},"ISSN":["0944-7113"],"issn-type":[{"value":"0944-7113","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activity of Artemisia annua and artemisinin derivatives, in prostate carcinoma","name":"articletitle","label":"Article Title"},{"value":"Phytomedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phymed.2015.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier GmbH. All rights reserved.","name":"copyright","label":"Copyright"}]}}